This review examines the neural mechanisms underlying migraine photophobia, focusing on the dual-pathway model established by Noseda et al. (2010, 2016). Photophobia affects 80-90% of migraine patients during ictal episodes and approximately 60% interictally. In India, with an estimated 213 million migraine cases (Global Burden of Disease 2019, The Lancet), approximately 170-190 million individuals experience clinically significant light sensitivity. The review covers: (1) Clinical classification of ictal versus interictal photophobia with a proposed severity grading framework; (2) The ipRGC-thalamic convergence pathway (Noseda et al. 2010, Nature Neuroscience), wherein melanopsin-expressing intrinsically photosensitive retinal ganglion cells (ipRGCs) project to posterior thalamic neurons that also receive trigeminal nociceptive input, producing supra-additive pain amplification; (3) The dual-pathway model (Noseda et al. 2016, Brain), identifying both melanopsin/ipRGC-mediated (460-520 nm) and cone-driven (585-600 nm) pain exacerbation pathways, with green light (~530 nm) uniquely reducing headache intensity; (4) The dark adaptation paradox, documenting how indoor sunglass use paradoxically worsens photophobia through progressive retinal sensitisation; (5) Published clinical evidence for FL-41 wavelength-selective filtration, including >50% migraine frequency reduction (Good et al. 1991), 71% patient preference in blepharospasm (Blackburn et al. 2009), and 76% neural pathway improvement (Reyes et al. 2024); and (6) Dual-band filtration approaches targeting both identified pain pathways while preserving the beneficial green band. The paper includes 5 tables covering photophobia severity grading, wavelength-dependent pain modulation, Indian epidemiological burden, FL-41 clinical evidence summary, and a proposed non-pharmacological management framework. 20 peer-reviewed references are cited. Authors: Suraj Dubey (Senior Optometrist, Founder & Head of R&D, Sleepaxa Private Limited; ORCID: 0009-0003-7510-9254; Inventor: Patent IN 202521094370, Patent Application IN 202521120977) and Monica Choudhary (Director MCVI; Ex-AIIMS Professor; Founding Member, Clinical Advisory Board, Sleepaxa Private Limited). Sleepaxa Private Limited is India's first photobiological eyewear company (DPIIT Recognised, CTRI Registered, Wikidata Q138837663).